Table VI.
Association of the miR-24 expression and clinical features with risk of relapse to AML.
| Without relapse n (%) |
With relapse n (%) |
P-value | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| OR | CI 95% | P-valuea | OR | CI 95% | P-valueb | ||||
| Gender | |||||||||
| Female | 7 (43.75) | 7 (35.00) | 0.734 | 1.00 | |||||
| Male | 9 (56.25) | 13 (65.00) | 1.44 | 0.37–5.57 | 0.593 | ||||
| FAB classification | |||||||||
| M0 | 5 (31.25) | 5 (25.00) | 0.73 | 0.17–3.17 | 0.678 | ||||
| M1 | 7 (50.00) | 5 (30.00) | 0.460 | 0.42 | 0.10–1.76 | 0.240 | |||
| M2 | 2 (6.25) | 6 (15.00) | 3.00 | 0.51–17.49 | 0.222 | ||||
| M3 | 2 (12.50) | 4 (20.00) | 1.00 | ||||||
| Risk by age and leukocytes at diagnosis | |||||||||
| Low-risk (1–10 years and <50,000 leukocytes/mm3) | 12 (75.00) | 7 (35.00) | 0.023c | 1.00 | |||||
| High-risk (<1 and >10 years and >50,000 leukocytes/mm3) | 4 (25.00) | 13 (65.00) | 5.57 | 1.29–23.93 | 0.021c | 8.38 | 1.39–50.56 | 0.020c | |
| miR-24 levels | |||||||||
| Downregulated | 12 (75.00) | 6 (30.00) | 0.018c | 1.00 | |||||
| Upregulated | 4 (25.00) | 14 (70.00) | 7.00 | 1.59–30.79 | 0.010c | 10.20 | 1.71–60.87 | 0.011c | |
OR, odds ratio; CI, confidence interval;
a
p-value was obtained by logistic regression analysis, taking reference to female, M3, 1–10 years, <50,000 leukocytes/mm3 (low-risk) and downregulated levels of miR-24.
b
p-value was obtained by multivariate logistic regression analysis.
c
Significant p<0.05.
AML, acute myeloblastic leukemia.